Konstantin Sharlovskiy, Head of the Life Sciences Practice at Pepeliaev Group, has been elected as a partner of the firm.
Konstantin has been providing assistance to pharmaceutical companies in Russia and the CIS for 13 years. He specialises in transactions with assets in the area of pharmaceuticals, solving complex regulatory issues, including those connected with intellectual property of pharmaceutical companies, with the localisation of manufacturing in Russia, and with contractual relationships between those involved in the circulation of medicines and medical products.
“The Life Sciences Practice has always been strategically important to us, and in recent years has gained even more momentum due to the economic and political environment,” comments Managing Partner, Sergey Pepeliaev. “Konstantin has faced serious challenges: the coronavirus pandemic as well as the “epidemic” of sanctions. Our Life Sciences Practice has faced up to all these challenges with a full readiness to help clients, protect their businesses and offer new solutions to complex business problems. As a result, our client base and the number of projects have grown significantly. For this reason, Konstantin fully deserves his elevation to the partnership. I am sure that this step will benefit the firm. Moreover, our clients will take pleasure in hearing this piece of news.”
“I am grateful to the partners for their trust and recognition of my achievements at this firm,” remarks Konstantin Sharlovskiy. “Since I have become the head of the practice, we have had the good fortune to implement many interesting, innovative and large-scale projects, but I believe that the greatest successes are yet to come. With the team we have, it could hardly be otherwise.”